Literature DB >> 9794902

Lipoprotein-X in patients with cirrhosis: its relationship to cholestasis and hypercholesterolemia.

P Sörös1, J Böttcher, H Maschek, O Selberg, M J Müller.   

Abstract

Lipoprotein-X (Lp-X) is an abnormal low-density lipoprotein frequently found in liver disease. It is regarded as the most sensitive and specific biochemical parameter for the diagnosis of intra- and extrahepatic cholestasis. Moreover, Lp-X is supposed to contribute to the development of hypercholesterolemia in cholestatic liver disease, because it fails to inhibit de novo cholesterol synthesis. This investigation will focus on the relationship between the presence of Lp-X and serum lipid concentrations in cirrhosis. The significance of Lp-X in the diagnosis of cholestasis, compared with alkaline phosphatase (AP), gamma-glutamyl transferase (GGT), and bilirubin levels, will be assessed as well. The present cross-sectional study includes 212 patients with histopathologically proven cirrhosis. The detection of Lp-X and the quantification of -, beta-, and pre-beta-cholesterol was based on agar gel electrophoresis and polyanion precipitation. For the characterization of liver function, the concentrations of albumin and bilirubin, the activities of liver enzymes, and coagulation times were assessed. In a subgroup of 40 individuals, liver biopsies were re-evaluated to confirm or exclude intrahepatic cholestasis. As a result, there was no association between the appearance of Lp-X and total cholesterol concentrations. While all patients with Lp-X showed intrahepatic cholestasis (predictive value of the positive test = 1), only 16 of 28 patients with cholestasis formed Lp-X (sensitivity = 0.57). The activities of AP and of GGT, as well as the concentrations of bilirubin, were strongly elevated in most patients, with and without cholestasis. The predictive values of AP, GGT, and bilirubin were 0.77, 0.69, and 0.74 for the positive test and 0.5, 0, and 0.6 for the negative test, respectively. We conclude that Lp-X is not related to hypercholesterolemia in cirrhosis. The positive, but not the negative, Lp-X test has high predictive value for the diagnosis of cholestasis in cirrhosis. The biochemical parameters traditionally used for the assessment of extrahepatic cholestasis, AP, GGT, and bilirubin, do not support the diagnosis of intrahepatic cholestasis caused by cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9794902     DOI: 10.1002/hep.510280506

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

1.  Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis.

Authors:  M Allocca; A Crosignani; A Gritti; G Ghilardi; D Gobatti; D Caruso; M Zuin; M Podda; P M Battezzati
Journal:  Gut       Date:  2006-04-21       Impact factor: 23.059

2.  LCAT Enzyme Replacement Therapy Reduces LpX and Improves Kidney Function in a Mouse Model of Familial LCAT Deficiency.

Authors:  Boris L Vaisman; Edward B Neufeld; Lita A Freeman; Scott M Gordon; Maureen L Sampson; Milton Pryor; Emily Hillman; Milton J Axley; Sotirios K Karathanasis; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2018-12-18       Impact factor: 4.030

3.  Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis.

Authors:  Eric J Brandt; Shane M Regnier; Edward Ky Leung; Sharon H Chou; Beverly W Baron; Helen S Te; Michael H Davidson; Robert M Sargis
Journal:  Clin Lipidol       Date:  2015-08-01

4.  Detection of Lipoprotein X (LpX): A challenge in patients with severe hypercholesterolaemia.

Authors:  Agnieszka Ćwiklińska; Agnieszka Mickiewicz; Robert Kowalski; Barbara Kortas-Stempak; Agnieszka Kuchta; Krzysztof Mucha; Michał Makowiecki; Anna Gliwińska; Krzysztof Lewandowski; Leszek Pączek; Marcin Fijałkowski; Marcin Gruchała; Maciej Jankowski
Journal:  J Med Biochem       Date:  2020-09-02       Impact factor: 3.402

5.  A Simple Fluorescent Cholesterol Labeling Method to Cryoprotect and Detect Plasma Lipoprotein-X.

Authors:  Edward B Neufeld; Lita A Freeman; Vinay Durbhakula; Maureen L Sampson; Robert D Shamburek; Sotirios K Karathanasis; Alan T Remaley
Journal:  Biology (Basel)       Date:  2022-08-22

Review 6.  Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Yingxue Lu; Xiaojing Ma; Jie Pan; Rongqiang Ma; Yujie Jiang
Journal:  Lipids Health Dis       Date:  2022-08-02       Impact factor: 4.315

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.